A M Kuijpers1, M Hauptmann2, A G Aalbers3, S W Nienhuijs4, I H de Hingh4, M J Wiezer5, B van Ramshorst5, R J van Ginkel6, K Havenga6, V J Verwaal3. 1. Department of Surgical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: a.kuijpers@nki.nl. 2. Department of Epidemiology and Biostatistics, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 3. Department of Surgical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 4. Department of Surgery, Catharina Hospital Eindhoven, The Netherlands. 5. Department of Surgery, Sint Antonius Hospital Nieuwegein, The Netherlands. 6. Department of Surgery, University Medical Center Groningen, The Netherlands.
Abstract
BACKGROUND: CytoReductive Surgery and Hyperthermic IntraPEritoneal Chemotherapy (CRS-HIPEC) is now the preferred treatment of many peritoneal surface malignancies. In this retrospective study we aimed to analyze how several performance indicators changed during the first 100 CRS-HIPEC procedures in hospitals which recently introduced this treatment, and compare those with an experienced institution. METHODS: The first consecutive 100 CRS-HIPEC procedures of three institutions were compared to those of the pioneer hospital. The training provided by the pioneer hospital consisted of hands-on training during the first ten procedures; hereafter guidance was available on consult basis. Operation characteristics, morbidity and completeness of cytoreduction were evaluated by case sequence. Locally-estimated-scatter-plot smoothing was used to evaluate the learning curve. RESULTS: From four institutions 372 cases were included. A macroscopic complete cytoreduction was reached in 66% of the cases in the pioneer hospital and in 86% in the new hospitals (p < 0.001). Complete cytoreduction rates were higher at start off in the new institutions compared with the experienced institution and increased significantly in the first 100 procedures. The new hospitals started with lower morbidity than the experienced hospital, which did not significantly decrease during the study period. CONCLUSION: New institutions that were trained and mentored by an experienced CRS-HIPEC hospital performed better from the beginning with regard to complete cytoreduction and morbidity rate with than the experienced center. An improvement in complete cytoreduction rate during the first 100 procedures was observed in the new institutions.
BACKGROUND: CytoReductive Surgery and Hyperthermic IntraPEritoneal Chemotherapy (CRS-HIPEC) is now the preferred treatment of many peritoneal surface malignancies. In this retrospective study we aimed to analyze how several performance indicators changed during the first 100 CRS-HIPEC procedures in hospitals which recently introduced this treatment, and compare those with an experienced institution. METHODS: The first consecutive 100 CRS-HIPEC procedures of three institutions were compared to those of the pioneer hospital. The training provided by the pioneer hospital consisted of hands-on training during the first ten procedures; hereafter guidance was available on consult basis. Operation characteristics, morbidity and completeness of cytoreduction were evaluated by case sequence. Locally-estimated-scatter-plot smoothing was used to evaluate the learning curve. RESULTS: From four institutions 372 cases were included. A macroscopic complete cytoreduction was reached in 66% of the cases in the pioneer hospital and in 86% in the new hospitals (p < 0.001). Complete cytoreduction rates were higher at start off in the new institutions compared with the experienced institution and increased significantly in the first 100 procedures. The new hospitals started with lower morbidity than the experienced hospital, which did not significantly decrease during the study period. CONCLUSION: New institutions that were trained and mentored by an experienced CRS-HIPEC hospital performed better from the beginning with regard to complete cytoreduction and morbidity rate with than the experienced center. An improvement in complete cytoreduction rate during the first 100 procedures was observed in the new institutions.
Authors: James W Jakub; Alicia M Terando; Amod Sarnaik; Charlotte E Ariyan; Mark B Faries; Sabino Zani; Heather B Neuman; Nabil Wasif; Jeffrey M Farma; Bruce J Averbook; Karl Y Bilimoria; Jacob B Jake Allred; Vera J Suman; Travis E Grotz; Benjamin Zendejas; Jeffrey D Wayne; Douglas S Tyler Journal: J Am Coll Surg Date: 2015-11-25 Impact factor: 6.113
Authors: Eun Jung Park; Seung Hyuk Baik; Hyuk Hur; Byung Soh Min; Jeonghyun Kang; Yun Dae Han; Min Soo Cho; Kang Young Lee; Nam Kyu Kim Journal: Medicine (Baltimore) Date: 2017-05 Impact factor: 1.889
Authors: W J Koemans; R T van der Kaaij; H Boot; T Buffart; A A F A Veenhof; K J Hartemink; C Grootscholten; P Snaebjornsson; V P Retel; H van Tinteren; S Vanhoutvin; V van der Noort; A Houwink; C Hahn; A D R Huitema; M Lahaye; M Los; P van den Barselaar; O Imhof; A Aalbers; G M van Dam; B van Etten; B P L Wijnhoven; M D P Luyer; D Boerma; J W van Sandick Journal: BMC Cancer Date: 2019-05-06 Impact factor: 4.430
Authors: Nick Seyfried; Can Yurttas; Markus Burkard; Benedikt Oswald; Alexander Tolios; Franziska Herster; Joseph Kauer; Tarkan Jäger; Ingmar Königsrainer; Karolin Thiel; Markus Quante; Hans-Georg Rammensee; Sascha Venturelli; Matthias Schwab; Alfred Königsrainer; Stefan Beckert; Markus W Löffler Journal: Cancers (Basel) Date: 2022-02-24 Impact factor: 6.639
Authors: Michel Adamina; Maxime Warlaumont; Martin D Berger; Silvio Däster; Raphaël Delaloye; Antonia Digklia; Beat Gloor; Ralph Fritsch; Dieter Koeberle; Thibaud Koessler; Kuno Lehmann; Phaedra Müller; Ralph Peterli; Frédéric Ris; Thomas Steffen; Christian Stefan Weisshaupt; Martin Hübner Journal: Cancers (Basel) Date: 2022-09-01 Impact factor: 6.575
Authors: Femke A van der Zant; Bob J L Kooijman; Judith E K R Hentzen; Wijnand Helfrich; Emily M Ploeg; Robert J van Ginkel; Barbara L van Leeuwen; Lukas B Been; Joost M Klaase; Patrick H J Hemmer; Christian S van der Hilst; Schelto Kruijff Journal: BJS Open Date: 2022-09-02
Authors: Job P van Kooten; Nadine L de Boer; Marjolein Diepeveen; Cornelis Verhoef; Jacobus W A Burger; Alexandra R M Brandt-Kerkhof; Eva V E Madsen Journal: Pleura Peritoneum Date: 2021-03-24